Successful expansion of functional and stable regulatory T cells for immunotherapy in liver transplantation

Oncotarget

Volumn 7, Issue 7, 2016, Pages 7563-7577

  Safinia, Niloufar ^a   Vaikunthanathan, Trishan ^a   Fraser, Henrieta ^a   Thirkell, Sarah ^a   Lowe, Katie ^a   Blackmore, Laura ^b   Whitehouse, Gavin ^b   Martinez Llordella, Marc ^b   Jassem, Wayel ^b   Sanchez Fueyo, Alberto ^b   Lechler, Robert I ^a   Lombardi, Giovanna ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Immune response; Immunity; Immunology and microbiology section; Immunosuppression; Immunotherapy; Liver transplantation; Regulatory T cells; Tolerance

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 7 RECEPTOR; L SELECTIN; RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3; IMMUNOSUPPRESSIVE AGENT;

ALCOHOL LIVER CIRRHOSIS; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CRYOPRESERVATION; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LIVER TRANSPLANTATION; LYMPHOCYTE CULTURE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; SAFETY; ALCOHOL-RELATED DISORDERS; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; FOLLOW UP; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LIVER CIRRHOSIS; PROSPECTIVE STUDY; T LYMPHOCYTE; TH17 CELL;

ALCOHOL-RELATED DISORDERS; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PROSPECTIVE STUDIES; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84958817280     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6927     Document Type: Article

References (44)

1. Lerut J and Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2006; 6:1774-1780.
2. Benitez C, Londono MC, Miquel R, Manzia TM, Abraldes JG, Lozano JJ, Martinez-Llordella M, Lopez M, Angelico R, Bohne F, Sese P, Daoud F, Larcier P, Roelen DL, Claas F, Whitehouse G, et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology. 2013; 58:1824-1835.
3. Sakaguchi S, Sakaguchi N, Asano M, Itoh M and Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. Journal of immunology. 1995; 155:1151-1164.
4. Khattri R, Cox T, Yasayko SA and Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nature immunology. 2003; 4:337-342.
5. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M and Takahashi T. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunological reviews. 2001; 182:18-32.
6. Tsang JY, Tanriver Y, Jiang S, Xue SA, Ratnasothy K, Chen D, Stauss HJ, Bucy RP, Lombardi G and Lechler R. Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice. The Journal of clinical investigation. 2008; 118:3619-3628.
7. Sagoo P, Ali N, Garg G, Nestle FO, Lechler RI and Lombardi G. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Science translational medicine. 2011; 3:83ra42.
8. Putnam AL, Safinia N, Medvec A, Laszkowska M, Wray M, Mintz MA, Trotta E, Szot GL, Liu W, Lares A, Lee K, Laing A, Lechler RI, Riley JL, Bluestone JA, Lombardi G, et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2013; 13:3010-3020.
9. Xiao F, Ma L, Zhao M, Huang G, Mirenda V, Dorling A, Lechler R and Lombardi G. Ex vivo expanded human regulatory T cells delay islet allograft rejection via inhibiting islet-derived monocyte chemoattractant protein-1 production in CD34+ stem cells-reconstituted NOD-scid IL2rgammanull mice. PloS one. 2014; 9:e90387.
10. Li W, Carper K, Zheng XX, Kuhr CS, Reyes JD, Liang Y, Perkins DL, Thomson AW and Perkins JD. The role of Foxp3+ regulatory T cells in liver transplant tolerance. Transplantation proceedings. 2006; 38:3205-3206.
11. Li Y, Koshiba T, Yoshizawa A, Yonekawa Y, Masuda K, Ito A, Ueda M, Mori T, Kawamoto H, Tanaka Y, Sakaguchi S, Minato N, Wood KJ and Tanaka K. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2004; 4:2118-2125.
12. Demirkiran A, Kok A, Kwekkeboom J, Kusters JG, Metselaar HJ, Tilanus HW and van der Laan LJ. Low circulating regulatory T-cell levels after acute rejection in liver transplantation. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2006; 12:277-284.
13. Trzonkowski P, Bieniaszewska M, Juscinska J, Dobyszuk A, Krzystyniak A, Marek N, Mysliwska J and Hellmann A. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127-T regulatory cells. Clinical immunology. 2009; 133:22-26.
14. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, Del Papa B, Zei T, Ostini RI, Cecchini D, Aloisi T, Perruccio K, Ruggeri L, Balucani C, Pierini A, Sportoletti P, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011; 117:3921-3928.
15. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, Defor T, Levine BL, June CH, Rubinstein P, McGlave PB, Blazar BR and Wagner JE. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011; 117:1061-1070.
16. Marek-Trzonkowska N, Mysliwiec M, Dobyszuk A, Grabowska M, Techmanska I, Juscinska J, Wujtewicz MA, Witkowski P, Mlynarski W, Balcerska A, Mysliwska J and Trzonkowski P. Administration of CD4+CD25highCD127-regulatory T cells preserves beta-cell function in type 1 diabetes in children. Diabetes Care. 2012; 35:1817-1820.
17. Afzali B, Edozie FC, Fazekasova H, Scotta C, Mitchell PJ, Canavan JB, Kordasti SY, Chana PS, Ellis R, Lord GM, John S, Hilton R, Lechler RI and Lombardi G. Comparison of regulatory T cells in hemodialysis patients and healthy controls: implications for cell therapy in transplantation. Clinical journal of the American Society of Nephrology: CJASN. 2013; 8:1396-1405.
18. Scotta C, Esposito M, Fazekasova H, Fanelli G, Edozie FC, Ali N, Xiao F, Peakman M, Afzali B, Sagoo P, Lechler RI and Lombardi G. Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4(+)CD25(+)FOXP3(+) T regulatory cell subpopulations. Haematologica. 2013; 98:1291-1299.
19. Golovina TN, Mikheeva T, Brusko TM, Blazar BR, Bluestone JA and Riley JL. Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PloS one. 2011; 6:e15868.
20. Hori S and Sakaguchi S. Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes and infection/Institut Pasteur. 2004; 6:745-751.
21. Hoffmann P, Boeld TJ, Eder R, Huehn J, Floess S, Wieczorek G, Olek S, Dietmaier W, Andreesen R and Edinger M. Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation. European journal of immunology. 2009; 39:1088-1097.
22. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF and Bluestone JA. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. The Journal of experimental medicine. 2006; 203:1701-1711.
23. Sansom DM and Walker LS. The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunological reviews. 2006; 212:131-148.
24. Read S, Malmstrom V and Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. The Journal of experimental medicine. 2000; 192:295-302.
25. Annunziato F, Cosmi L, Liotta F, Lazzeri E, Manetti R, Vanini V, Romagnani P, Maggi E and Romagnani S. Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes. The Journal of experimental medicine. 2002; 196:379-387.
26. Ochando JC, Yopp AC, Yang Y, Garin A, Li Y, Boros P, Llodra J, Ding Y, Lira SA, Krieger NR and Bromberg JS. Lymph node occupancy is required for the peripheral development of alloantigen-specific Foxp3+ regulatory T cells. Journal of immunology. 2005; 174:6993-7005.
27. Oo YH, Weston CJ, Lalor PF, Curbishley SM, Withers DR, Reynolds GM, Shetty S, Harki J, Shaw JC, Eksteen B, Hubscher SG, Walker LS and Adams DH. Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. Journal of immunology. 2010; 184:2886-2898.
28. Hori S. Developmental plasticity of Foxp3+ regulatory T cells. Current opinion in immunology. 2010; 22:575-582.
29. Li L and Boussiotis VA. The role of IL-17-producing Foxp3+ CD4+ T cells in inflammatory bowel disease and colon cancer. Clinical immunology. 2013; 148:246-253.
30. Pesenacker AM, Bending D, Ursu S, Wu Q, Nistala K and Wedderburn LR. CD161 defines the subset of FoxP3+ T cells capable of producing proinflammatory cytokines. Blood. 2013; 121:2647-2658.
31. Maggi L, Santarlasci V, Capone M, Peired A, Frosali F, Crome SQ, Querci V, Fambrini M, Liotta F, Levings MK, Maggi E, Cosmi L, Romagnani S and Annunziato F. CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC. European journal of immunology. 2010; 40:2174-2181.
32. Cosmi L, De Palma R, Santarlasci V, Maggi L, Capone M, Frosali F, Rodolico G, Querci V, Abbate G, Angeli R, Berrino L, Fambrini M, Caproni M, Tonelli F, Lazzeri E, Parronchi P, et al. Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. The Journal of experimental medicine. 2008; 205:1903-1916.
33. Afzali B, Mitchell PJ, Edozie FC, Povoleri GA, Dowson SE, Demandt L, Walter G, Canavan JB, Scotta C, Menon B, Chana PS, Khamri W, Kordasti SY, Heck S, Grimbacher B, Tree T, et al. CD161 expression characterizes a subpopulation of human regulatory T cells that produces IL-17 in a STAT3-dependent manner. European journal of immunology. 2013; 43:2043-2054.
34. Benitez CE, Puig-Pey I, Lopez M, Martinez-Llordella M, Lozano JJ, Bohne F, Londono MC, Garcia-Valdecasas JC, Bruguera M, Navasa M, Rimola A and Sanchez-Fueyo A. ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2010; 10:2296-2304.
35. Marek N, Bieniaszewska M, Krzystyniak A, Juscinska J, Mysliwska J, Witkowski P, Hellmann A and Trzonkowski P. The time is crucial for ex vivo expansion of T regulatory cells for therapy. Cell transplantation. 2011; 20:1747-1758.
36. King MA, Covassin L, Brehm MA, Racki W, Pearson T, Leif J, Laning J, Fodor W, Foreman O, Burzenski L, Chase TH, Gott B, Rossini AA, Bortell R, Shultz LD and Greiner DL. Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clinical and experimental immunology. 2009; 157:104-118.
37. Tresoldi E, Dell'albani I, Stabilini A, Jofra T, Valle A, Gagliani N, Bondanza A, Roncarolo MG and Battaglia M. Stability of human rapamycin-expanded CD4+CD25+ T regulatory cells. Haematologica. 2011; 96:1357-1365.
38. Kopf H, de la Rosa GM, Howard OM and Chen X. Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells. International immunopharmacology. 2007; 7:1819-1824.
39. Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, Koch AE, Moser B and Mackay CR. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. The Journal of clinical investigation. 1998; 101:746-754.
40. Lapierre P, Beland K, Yang R and Alvarez F. Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance. Hepatology. 2013; 57:217-227.
41. Wells AD, Li XC, Li Y, Walsh MC, Zheng XX, Wu Z, Nunez G, Tang A, Sayegh M, Hancock WW, Strom TB and Turka LA. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nature medicine. 1999; 5:1303-1307.
42. Xia G, He J and Leventhal JR. Ex vivo-expanded natural CD4+CD25+ regulatory T cells synergize with host T-cell depletion to promote long-term survival of allografts. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2008; 8:298-306.
43. Lopez M, Clarkson MR, Albin M, Sayegh MH and Najafian N. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. Journal of the American Society of Nephrology: JASN. 2006; 17:2844-2853.
44. Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A and Zippelius A. Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. Journal of immunology. 2007; 178:320-329.